A Multi-Center, Open-Label Study of Fruquintinib in Solid Tumors and Colorectal, and Breast Cancers

NCT03251378 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

129

Enrollment

INDUSTRY

Sponsor class

Conditions

Advanced Solid Tumors
Metastatic Colon Cancer
Metastatic Breast Cancer
Triple Negative Breast Cancer
HER2-negative Breast Cancer
Hormone Receptor Positive Breast Carcinoma
Rectal Cancer

Interventions

DRUG: Fruquintinib (HMPL-013)

Sponsor

Hutchison Medipharma Limited